Swiss National Bank Cuts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Swiss National Bank cut its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRYFree Report) by 19.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 66,000 shares of the company’s stock after selling 16,300 shares during the quarter. Swiss National Bank owned approximately 0.07% of ARS Pharmaceuticals worth $362,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SPRY. Nisa Investment Advisors LLC boosted its stake in ARS Pharmaceuticals by 22,300.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after acquiring an additional 5,575 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of ARS Pharmaceuticals by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after buying an additional 8,652 shares in the last quarter. Letko Brosseau & Associates Inc. purchased a new stake in shares of ARS Pharmaceuticals during the 3rd quarter valued at approximately $136,000. Bank of New York Mellon Corp lifted its stake in shares of ARS Pharmaceuticals by 9.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 83,924 shares of the company’s stock valued at $317,000 after buying an additional 7,024 shares in the last quarter. Finally, Denali Advisors LLC purchased a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at approximately $480,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Stock Down 0.3 %

Shares of SPRY opened at $8.88 on Monday. The stock has a market capitalization of $860.38 million, a P/E ratio of -17.08 and a beta of 0.88. The firm has a fifty day simple moving average of $9.10 and a two-hundred day simple moving average of $7.41. ARS Pharmaceuticals, Inc. has a twelve month low of $2.55 and a twelve month high of $11.27.

ARS Pharmaceuticals (NASDAQ:SPRYGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Sell-side analysts expect that ARS Pharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, Director Ra Capital Management, L.P. acquired 505,954 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, March 27th. The stock was acquired at an average cost of $9.79 per share, for a total transaction of $4,953,289.66. Following the purchase, the director now owns 9,958,073 shares in the company, valued at $97,489,534.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total value of $928,000.00. Following the transaction, the insider now owns 1,647,447 shares of the company’s stock, valued at $15,288,308.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ra Capital Management, L.P. acquired 505,954 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was acquired at an average cost of $9.79 per share, for a total transaction of $4,953,289.66. Following the acquisition, the director now owns 9,958,073 shares of the company’s stock, valued at approximately $97,489,534.67. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 600,000 shares of company stock worth $5,520,743. 40.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the stock. William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $6.00 to $18.00 in a research note on Tuesday, March 5th. Leerink Partnrs upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. Finally, Wedbush restated an “outperform” rating and set a $19.00 price target on shares of ARS Pharmaceuticals in a research note on Monday, March 11th.

View Our Latest Stock Report on ARS Pharmaceuticals

ARS Pharmaceuticals Company Profile

(Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Featured Articles

Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRYFree Report).

Institutional Ownership by Quarter for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.